Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Morgan Stanley from $8.00 to $4.00. They now have an "overweight" rating on the stock.
We Think Some Shareholders May Hesitate To Increase Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO Compensation [Yahoo! Finance]
NeraCare Announces Publication of Abstract on Clinical Validation of a Prognostic 7-Biomarker Assay for Prediction of Relapse in Patients with Early-Stage Cutaneous Melanoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! F
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $10.00 to $6.00. They now have a "buy" rating on the stock.
Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at BTIG Research from $9.00 to $6.00. They now have a "buy" rating on the stock.